NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 2.2023
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC.
Category
  • Lung Cancers
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Updates in Biomarker Testing in Non-Small Cell Lung Cancer
Biomarker testing is becoming more important due to the shift in cancer care to targeted therapies. Especially in NSCLC, there are many new updates in which biomarkers should be tested, when testing is required or recommended, and what the barriers are to implementing testing for all patients.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 ANCC contact hours
  • 0.75 Participation
Archived Monthly Oncology Tumor Boards: Neoadjuvant and Adjuvant Therapy for Patients with Resectable Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Clinicians need to know the nuances of using neoadjuvant and adjuvant targeted therapy and immunotherapy to improve outcomes for their patients with resected early-stage and locally advanced NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Screening for Lung Cancer: An Expert Review
Lung cancer screening has been shown to be an effective tool in decreasing lung cancer-related mortality and is recommended by several organizations, including NCCN. However, overall use of appropriate screening for high-risk patients remains low. Provider education may increase screening utilization and improve patient outcomes for those living with lung cancer.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Targeted Therapy for Metastatic Non-Small Cell Lung Cancer
Clinicians need to be aware of the most recent recommendations about biomarker testing and the appropriate use of new targeted therapies (including sequencing these therapies, assessing and managing side effects from these therapies), so they can select the most appropriate therapy for their patients with metastatic NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Challenging Case Review: Non-Small Cell Lung Cancer
As a result of the therapeutic advances and clinical research affecting the management of patients with non-small cell lung cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Clinical Scenario #4: Applying Biomarkers in Non-Small Cell Lung Cancer
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Unlocking the Potential of Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The Role of Checkpoint Inhibitors
The goal of this initiative is to provide education to assist clinicians in providing appropriate care for patients with non-small cell lung cancer (NSCLC) through a greater understanding of the significance of biomarker testing to predict treatment response, the role of PD-1/PD-L1 inhibitors in
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.75 AAPA Category 1 CME credit
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation